JPH11504635A - コレステリルエステル転移タンパク質(cetp)活性の調節 - Google Patents
コレステリルエステル転移タンパク質(cetp)活性の調節Info
- Publication number
- JPH11504635A JPH11504635A JP8533487A JP53348796A JPH11504635A JP H11504635 A JPH11504635 A JP H11504635A JP 8533487 A JP8533487 A JP 8533487A JP 53348796 A JP53348796 A JP 53348796A JP H11504635 A JPH11504635 A JP H11504635A
- Authority
- JP
- Japan
- Prior art keywords
- cell epitope
- vaccine
- cetp
- peptide
- helper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 51
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 title abstract description 186
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 title abstract description 186
- 230000033228 biological regulation Effects 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 229
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 112
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 89
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 33
- 229960005486 vaccine Drugs 0.000 claims description 167
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 120
- 235000001014 amino acid Nutrition 0.000 claims description 73
- 150000001413 amino acids Chemical class 0.000 claims description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 50
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims description 49
- 235000012000 cholesterol Nutrition 0.000 claims description 48
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 46
- 230000027455 binding Effects 0.000 claims description 42
- 102000052454 human CETP Human genes 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 235000018102 proteins Nutrition 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 230000000890 antigenic effect Effects 0.000 claims description 23
- 238000012546 transfer Methods 0.000 claims description 20
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 19
- 230000003902 lesion Effects 0.000 claims description 19
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 230000007935 neutral effect Effects 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 13
- 229940118376 tetanus toxin Drugs 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 11
- 241000282412 Homo Species 0.000 claims description 10
- 210000000981 epithelium Anatomy 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 230000003143 atherosclerotic effect Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- 229940041323 measles vaccine Drugs 0.000 claims description 7
- 229960003131 rubella vaccine Drugs 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 229940095293 mumps vaccine Drugs 0.000 claims description 6
- 229960001539 poliomyelitis vaccine Drugs 0.000 claims description 6
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 claims description 5
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 5
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 5
- 101150031823 HSP70 gene Proteins 0.000 claims description 5
- 101150052825 dnaK gene Proteins 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 claims description 4
- 102000000989 Complement System Proteins Human genes 0.000 claims description 3
- 108010069112 Complement System Proteins Proteins 0.000 claims description 3
- 102000043129 MHC class I family Human genes 0.000 claims description 3
- 108091054437 MHC class I family Proteins 0.000 claims description 3
- 229940066827 pertussis vaccine Drugs 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 2
- 229960001005 tuberculin Drugs 0.000 claims description 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 13
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 8
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 8
- 241000588832 Bordetella pertussis Species 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 2
- 241001669573 Galeorhinus galeus Species 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 15
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 97
- 102000004196 processed proteins & peptides Human genes 0.000 description 52
- 102000015779 HDL Lipoproteins Human genes 0.000 description 45
- 238000002965 ELISA Methods 0.000 description 26
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 239000002671 adjuvant Substances 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 20
- 102000004895 Lipoproteins Human genes 0.000 description 18
- 108090001030 Lipoproteins Proteins 0.000 description 18
- 102100037624 Nuclear transition protein 2 Human genes 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- -1 cholesteryl ester Chemical class 0.000 description 15
- 239000003925 fat Substances 0.000 description 15
- 239000004971 Cross linker Substances 0.000 description 14
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 229940098773 bovine serum albumin Drugs 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000003244 etp Anatomy 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000011534 wash buffer Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 102000003992 Peroxidases Human genes 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 7
- 230000001588 bifunctional effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 206010043376 Tetanus Diseases 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229940031348 multivalent vaccine Drugs 0.000 description 4
- 229940023041 peptide vaccine Drugs 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 240000003291 Armoracia rusticana Species 0.000 description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000004576 lipid-binding Effects 0.000 description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 235000020030 perry Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 2
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 2
- 102000011772 Apolipoprotein C-I Human genes 0.000 description 2
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 2
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 2
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 101150069040 CETP gene Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000489 anti-atherogenic effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000016178 immune complex formation Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940126577 synthetic vaccine Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- VLWQPMPFPUXBLV-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)butanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.OC(=O)CCCN1C(=O)C=CC1=O VLWQPMPFPUXBLV-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 101800001976 Apolipoprotein B-48 Proteins 0.000 description 1
- 102400000352 Apolipoprotein B-48 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108700012841 Cholesteryl Ester Transfer Protein Deficiency Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010080123 HDL-triglyceride Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108700009457 Mycobacterium tuberculosis HSP70 Proteins 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 101800005164 Peptide V Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 1
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101150009841 TP gene Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000000407 epitaxy Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 239000008008 oral excipient Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.広域ヘルパーT細胞エピトープを含有するヘルパーT細胞エピトープ部分と 、CETPのB細胞エピトープを含有するB細胞エピトープ部分と、を含んでな る単離されたペプチド。 2.B細胞エピトープ部分がB細胞または抗体により認識される配列番号4の少 なくとも6個の連続アミノ酸からなるヒトCETPの一部を含有する、請求項1 に記載の単離されたペプチド。 3.CETPのB細胞エピトープが、配列番号4のアミノ酸349〜367によ り規定されるアミノ酸配列、配列番号4のアミノ酸461〜476により規定さ れるアミノ酸配列、抗原エピトープ同定アルゴリズムにより同定されたアミノ酸 配列、中性脂肪結合に関与する領域、中性脂肪転移活性に関与する領域よりなる 群から選択される、請求項1に記載の単離されたペプチド。 4.ヘルパーT細胞エピトープ部分が破傷風毒素、ジフテリア毒素、百日咳菌ワ クチン、カルメット- ゲラン杆菌(BCG)、ポリオワクチン、麻疹ワクチン、 おたふくかぜワクチン、風疹ワクチン、ツベルクリンの精製タンパク質誘導体、 キーホールリンペットヘモシアニン、hsp70およびこれらの組合せよりなる 群から選択される抗原性ペプチドから誘導されたヘルパーT細胞エピトープを含 有する、請求項1に記載の単離されたペプチド。 5.B細胞エピトープ部分がヒトCETP(配列番号1)のカルボキシル末端の 26アミノ酸の6〜26個の連続アミノ酸からなるペプチドである、請求項2に 記載の単離されたペプチド。 6.B細胞エピトープ部分が中性脂肪結合または中性脂肪転移活性を有するCE TPの誘導体である、請求項2に記載の単離されたペプチド。 7.アミノ末端システイン残基を有する、請求項1に記載の単離されたペプチド 。 8.配列番号2のアミノ酸配列を含んでなる、請求項1に記載の単離されたペプ チド。 9.CETPのB細胞エピトープを含有するB細胞エピトープ部分に結合された 普遍ヘルパーT細胞エピトープ部分を含んでなるワクチンペプチドを含有する ワクチン。 10.ワクチンペプチドのT細胞エピトープ部分が破傷風毒素、ジフテリア毒素、 百日咳菌ワクチン、カルメット- ゲラン杆菌(BCG)、ポリオワクチン、麻疹 ワクチン、おたふくかぜワクチン、風疹ワクチン、ツベルクリンの精製タンパク 質誘導体、キーホールリンペットヘモシアニン、hsp70およびこれらの組合 せよりなる群から選択される抗原性ペプチドから誘導されたヘルパーT細胞エピ トープを含有する、請求項9に記載のワクチン。 11.ワクチンペプチドのヘルパーT細胞エピトープ部分が破傷風毒素タンパク質 のアミノ酸830〜843(配列番号2のアミノ酸2〜15)のアミノ酸配列、 破傷風毒素タンパク質(配列番号3)のアミノ酸947〜967のアミノ酸配列 、およびこれらの組合せよりなる群から選択されるヘルパーT細胞エピトープを 含有する、請求項9に記載のワクチン。 12.CETPがヒトCETPである、請求項9に記載のワクチン。 13.ワクチンペプチドのB細胞エピトープ部分がヒトCETP(配列番号1)の カルボキシル末端の26アミノ酸の6〜26個の連続アミノ酸よりなる群から選 択されるヒトCETPのB細胞エピトープを含有する、請求項12に記載のワク チン。 14.ワクチンペプチドがアミノ末端システイン残基をさらに含有する、請求項9 に記載のワクチン。 15.多コピー数の補体タンパク質C3dに共有結合されたワクチンペプチドをさ らに含有する、請求項9に記載のワクチン。 16.補体タンパク質C3dとin vivo で共有結合するようになる炭水化物構造に より誘導体化されたワクチンペプチドをさらに含有する、請求項9に記載のワク チン。 17.ヒトまたは他の動物における循環LDL、VLDLまたは総コレステロール に対する循環HDLの比率を高める方法であって、ヘルパーT細胞エピトープ部 分と、該ヒトまたは他の動物のCETPのB細胞エピトープを含有するB細胞エ ピトープ部分と、を含むワクチンペプチドを含有するワクチン組成物をヒトまた は動物に投与することを含んでなる方法。 18.B細胞エピトープ部分が中性脂肪結合または中性脂肪転移活性に関与するC ETPのカルボキシル末端領域を含有する、請求項17に記載の方法。 19.ワクチンペプチドのヘルパーT細胞エピトープ部分が破傷風毒素タンパク質 のアミノ酸830〜843(配列番号2のアミノ酸2〜16)のアミノ酸配列お よび配列番号3の破傷風毒素タンパク質のアミノ酸947〜967のアミノ酸配 列よりなる群から選択されるT細胞エピトープを含有する、請求項17に記載の 方法。 20.ワクチンペプチドのB細胞エピトープ部分が配列番号1の6〜26個の連続 アミノ酸よりなる群から選択される、請求項17に記載の方法。 21.ワクチンペプチドがアミノ末端システイン残基をさらに含有する、請求項1 7に記載の方法。 22.ヒトまたは他の動物における内因性CETP活性のレベルを低下させる方法 であって、ヒトまたは動物のCETPのB細胞エピトープを含有するB細胞エピ トープ部分に結合されたヘルパーT細胞エピトープ部分を含むワクチンペプチド をヒトまたは動物に投与することを含んでなる方法。 23.ワクチンペプチドがヒトまたは他の動物において抗CETP抗体の産生を引 き出すのに十分な量で投与される、請求項22に記載の方法。 24.HDL- コレステロールの異化作用を改変してヒトまたは他の動物のアテロ ーム性動脈硬化症病変の発生を低下させる方法であって、CETPのB細胞エピ トープを含有するB細胞エピトープ部分に結合された、広域T細胞エピトープを 含有するヘルパーT細胞エピトープ部分を含むワクチンペプチドをヒトまたは動 物に投与することを含んでなる方法。 25.ヒトまたは他の動物における循環HDLのレベルを増加させる方法であって 、ヘルパーT細胞エピトープ部分とヒトまたは他の動物のCETPのB細胞エピ トープを含有するB細胞エピトープ部分とを含むワクチンペプチドをヒトまたは 動物に投与することを含んでなる方法。 26.ヘルパーT細胞エピトープ部分が破傷風毒素、ジフテリア毒素、百日咳菌ワ クチン、カルメット- ゲラン杆菌(BCG)、ポリオワクチン、麻疹ワクチン、 おたふくかぜワクチン、風疹ワクチン、ツベルクリンの精製タンパク質誘導体、 キーホールリンペットヘモシアニンおよびこれらの組合せよりなる群から選択さ れる抗原性ペプチドから誘導されたヘルパーT細胞エピトープを含有する、請求 項25に記載の方法。 27.B細胞エピトープ部分が配列番号1の6〜26個の連続アミノ酸からなるヒ トCETPのカルボキシル末端領域を含有する、請求項25に記載の方法。 28.ヒトまたは他の動物のアテローム性動脈硬化症を治療的または予防的に処置 する方法であって、かかる処置を必要としているヒトまたは他の動物に、製薬上 許容される緩衝液中の、ヘルパーT細胞エピトープを含有するヘルパーT細胞エ ピトープ部分とCETPのB細胞エピトープを含有するB細胞エピトープ部分と を含むワクチンペプチドを投与することを含んでなる方法。 29.ヘルパーT細胞エピトープ部分が破傷風毒素、ジフテリア毒素、百日咳菌ワ クチン、カルメット- ゲラン杆菌(BCG)、ポリオワクチン、麻疹ワクチン、 おたふくかぜワクチン、風疹ワクチン、ツベルクリンの精製タンパク質誘導体、 キーホールリンペットヘモシアニン、hsp70およびこれらの組合せよりなる 群から選択される抗原性ペプチドから誘導されたヘルパーT細胞エピトープを含 有する、請求項28に記載のアテローム性動脈硬化症の処置方法。 30.内因性CETP活性を調節するためのまたはアテローム性動脈硬化症を治療 的または予防的に処置するための抗CETPワクチンを調製する方法であって、 主要組織適合性遺伝子複合体クラスIのT細胞エピトープを含まない、CE TPのB細胞エピトープを選択し、 CETPに由来しない抗原性ペプチドから誘導されたヘルパーT細胞エピト ープを選択し、そして CETPのB細胞エピトープとヘルパーT細胞エピトープを結合させて免疫 原性部分を形成させる、 ことを含んでなる方法。 31.B細胞エピトープ部分がヘルパーT細胞エピトープに共有結合される、請求 項30に記載の方法。 32.B細胞エピトープ部分がペプチド結合およびジスルフィド結合よりなる群か ら選択される共有結合を介してヘルパーT細胞エピトープに共有結合される、 請求項30に記載の方法。 33.B細胞エピトープ部分がリンカー分子を介してヘルパーT細胞エピトープに 結合される、請求項30に記載の方法。 34.B細胞エピトープ部分がアミノ酸橋を介してヘルパーT細胞エピトープに結 合される、請求項30に記載の方法。 35.B細胞エピトープ部分とヘルパーT細胞エピトープが1つの共通の担体分子 に結合される、請求項30に記載の方法。 36.B細胞エピトープ部分をヘルパーT細胞エピトープに結合させてワクチンペ プチドを形成し、このワクチンペプチドを1つの共通の担体分子に結合させる工 程をさらに含む、請求項30に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/432,483 US6410022B1 (en) | 1995-05-01 | 1995-05-01 | Modulation of cholesteryl ester transfer protein (CETP) activity |
US08/432,483 | 1995-05-01 | ||
PCT/US1996/006147 WO1996034888A1 (en) | 1995-05-01 | 1996-05-01 | Modulation of cholesteryl ester transfer protein (cetp) activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11504635A true JPH11504635A (ja) | 1999-04-27 |
JP3839483B2 JP3839483B2 (ja) | 2006-11-01 |
Family
ID=23716356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53348796A Expired - Fee Related JP3839483B2 (ja) | 1995-05-01 | 1996-05-01 | コレステリルエステル転移タンパク質(cetp)活性の調節 |
Country Status (10)
Country | Link |
---|---|
US (5) | US6410022B1 (ja) |
EP (1) | EP0827509B1 (ja) |
JP (1) | JP3839483B2 (ja) |
AT (1) | ATE336510T1 (ja) |
CA (1) | CA2219795C (ja) |
DE (1) | DE69636453T2 (ja) |
DK (1) | DK0827509T3 (ja) |
ES (1) | ES2271952T3 (ja) |
PT (1) | PT827509E (ja) |
WO (1) | WO1996034888A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003530074A (ja) * | 1999-08-03 | 2003-10-14 | ザ オハイオ ステイト ユニバーシティ | Her−2タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
JP2010535818A (ja) * | 2007-08-10 | 2010-11-25 | アフィリス・アクチェンゲゼルシャフト | アテローム性動脈硬化の治療 |
JP2013531673A (ja) * | 2010-07-08 | 2013-08-08 | ユナイテッド・バイオメディカル・インコーポレーテッド | デザイナーペプチドベースのpcv2ワクチン |
JP2016155813A (ja) * | 2013-03-29 | 2016-09-01 | 大日本住友製薬株式会社 | Wt1抗原ペプチドコンジュゲートワクチン |
US10588952B2 (en) | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410022B1 (en) * | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
CA2223177A1 (en) | 1995-06-06 | 1996-12-12 | The Immune Response Corporation | Method for increasing hdl cholesterol level |
ATE321559T1 (de) * | 1996-05-01 | 2006-04-15 | Avant Immunotherapeutics Inc | Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis |
US20030100520A1 (en) * | 1997-01-21 | 2003-05-29 | Philip Needleman | Immunological process and constructs for increasing the hdl cholesterol concentration by dna vaccination |
US20030026808A1 (en) * | 1997-01-21 | 2003-02-06 | Philip Needleman | An IMMUNOLOGICAL PROCESS FOR INCREASING THE HDL CHOLESTROL CONCENTRATION |
AU9231798A (en) * | 1997-09-19 | 1999-04-12 | Pharmacia Corporation | Dna vaccination against cholesterol ester transfer protein in the treatment of atherosclerosis |
EP1024825A1 (en) * | 1997-10-20 | 2000-08-09 | Avant Immunotherapeutics, Inc. | Xenogeneic cholesteryl ester transfer protein (cetp) for modulation of cetp activity |
US6875904B2 (en) | 2000-09-20 | 2005-04-05 | The Ohio State University Research Foundation | Animal model for identifying agents that inhibit or enhance CTLA4 signaling |
DE10121982B4 (de) * | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
AU2002325827A1 (en) * | 2001-06-07 | 2002-12-16 | Genfit | Compositions and methods for detecting or regulating cholesteryl ester transfer protein |
AU2003272188A1 (en) * | 2002-03-22 | 2004-01-06 | Thomas V. Tittle | Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines |
US20050054572A1 (en) * | 2003-07-03 | 2005-03-10 | Marshall Christopher P. | Methods for obtaining molecules with reduced immunogenicity |
AT500835B1 (de) * | 2004-09-13 | 2007-12-15 | Affiris Forschungs & Entwicklungs Gmbh | Cholinestertransport-protein-mimotop als atherosklerose-medikament |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US20060276400A1 (en) | 2005-06-06 | 2006-12-07 | Hedy Adari | Modulation of cholesteryl ester transfer protein (CETP) activity |
ES2531483T3 (es) | 2005-06-15 | 2015-03-16 | The Ohio State University Research Foundation | Péptidos HER-2 |
US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
EP2532359A1 (en) | 2011-06-10 | 2012-12-12 | Affiris AG | CETP fragments |
WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
MX347400B (es) | 2012-06-29 | 2017-04-18 | Univ Nac Autónoma De México | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. |
TW201627318A (zh) * | 2014-10-22 | 2016-08-01 | 臺北醫學大學 | 膽固醇酯轉運蛋白抗原肽及其融合蛋白以及其組合物及應用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143305A (en) * | 1973-05-07 | 2000-11-07 | The Ohio State University | Antigenically modified polypeptides composition |
US5126399A (en) | 1986-04-30 | 1992-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation and use of site-directed immunologic reagents |
US5338829A (en) | 1988-04-20 | 1994-08-16 | Trustees Of The University Of Pennsylvania | Peptides derived from human immunodeficiency virus-1 GP160 |
GB8812214D0 (en) | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
US5242687A (en) | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
EP0562020A4 (en) | 1990-12-10 | 1993-11-18 | Alving, Carl L. | A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis |
WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
AU4377793A (en) | 1992-05-20 | 1993-12-13 | Johns Hopkins University, The | Alternative receptor therapy |
US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
US5618683A (en) | 1993-04-13 | 1997-04-08 | Brocia; Robert W. | Diagnostic kit for cholesteryl ester transfer protein (CETP) activity measurement and a new synthetic particle used therein |
DK0708656T3 (da) | 1993-04-27 | 2002-12-02 | United Biomedical Inc | Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
US5705388A (en) | 1994-12-23 | 1998-01-06 | Ribozyme Pharmaceuticals, Inc. | CETP Ribozymes |
US6410022B1 (en) * | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
CA2223177A1 (en) | 1995-06-06 | 1996-12-12 | The Immune Response Corporation | Method for increasing hdl cholesterol level |
US5869057A (en) * | 1995-06-07 | 1999-02-09 | Rock; Edwin P. | Recombinant vaccines to break self-tolerance |
US5807552A (en) * | 1995-08-04 | 1998-09-15 | Board Of Regents, The University Of Texas System | Compositions for conferring immunogenicity to a substance and uses thereof |
-
1995
- 1995-05-01 US US08/432,483 patent/US6410022B1/en not_active Expired - Fee Related
-
1996
- 1996-05-01 US US08/945,289 patent/US6555113B1/en not_active Expired - Fee Related
- 1996-05-01 JP JP53348796A patent/JP3839483B2/ja not_active Expired - Fee Related
- 1996-05-01 PT PT96913320T patent/PT827509E/pt unknown
- 1996-05-01 WO PCT/US1996/006147 patent/WO1996034888A1/en active IP Right Grant
- 1996-05-01 CA CA002219795A patent/CA2219795C/en not_active Expired - Fee Related
- 1996-05-01 DE DE69636453T patent/DE69636453T2/de not_active Expired - Fee Related
- 1996-05-01 AT AT96913320T patent/ATE336510T1/de not_active IP Right Cessation
- 1996-05-01 EP EP96913320A patent/EP0827509B1/en not_active Expired - Lifetime
- 1996-05-01 ES ES96913320T patent/ES2271952T3/es not_active Expired - Lifetime
- 1996-05-01 DK DK96913320T patent/DK0827509T3/da active
-
2001
- 2001-08-30 US US09/943,334 patent/US7078036B2/en not_active Expired - Fee Related
- 2001-08-30 US US09/943,548 patent/US20020042364A1/en not_active Abandoned
-
2003
- 2003-01-08 US US10/339,522 patent/US20030108559A1/en not_active Abandoned
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003530074A (ja) * | 1999-08-03 | 2003-10-14 | ザ オハイオ ステイト ユニバーシティ | Her−2タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
JP4658423B2 (ja) * | 1999-08-03 | 2011-03-23 | ザ オハイオ ステイト ユニバーシティ | Her−2タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
JP2010535818A (ja) * | 2007-08-10 | 2010-11-25 | アフィリス・アクチェンゲゼルシャフト | アテローム性動脈硬化の治療 |
JP2014040438A (ja) * | 2007-08-10 | 2014-03-06 | Affiris Ag | アテローム性動脈硬化の治療 |
JP2013531673A (ja) * | 2010-07-08 | 2013-08-08 | ユナイテッド・バイオメディカル・インコーポレーテッド | デザイナーペプチドベースのpcv2ワクチン |
US9932372B2 (en) | 2010-07-08 | 2018-04-03 | United Biomedical, Inc. | Designer peptide-based PCV2 vaccine |
JP2016155813A (ja) * | 2013-03-29 | 2016-09-01 | 大日本住友製薬株式会社 | Wt1抗原ペプチドコンジュゲートワクチン |
JP2019069970A (ja) * | 2013-03-29 | 2019-05-09 | 大日本住友製薬株式会社 | Wt1抗原ペプチドコンジュゲートワクチン |
US10588952B2 (en) | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
US11759509B2 (en) | 2013-03-29 | 2023-09-19 | Sumitomo Pharma Co., Ltd. | WT1 antigen peptide conjugate vaccine |
Also Published As
Publication number | Publication date |
---|---|
DE69636453T2 (de) | 2007-03-29 |
AU707752B2 (en) | 1999-07-22 |
US6555113B1 (en) | 2003-04-29 |
US20020042364A1 (en) | 2002-04-11 |
EP0827509B1 (en) | 2006-08-16 |
PT827509E (pt) | 2007-01-31 |
DK0827509T3 (da) | 2006-12-27 |
US20040087481A1 (en) | 2004-05-06 |
CA2219795C (en) | 2000-08-08 |
US20030108559A1 (en) | 2003-06-12 |
JP3839483B2 (ja) | 2006-11-01 |
US7078036B2 (en) | 2006-07-18 |
ES2271952T3 (es) | 2007-04-16 |
ATE336510T1 (de) | 2006-09-15 |
CA2219795A1 (en) | 1996-11-07 |
EP0827509A1 (en) | 1998-03-11 |
AU5636096A (en) | 1996-11-21 |
DE69636453D1 (de) | 2006-09-28 |
US6410022B1 (en) | 2002-06-25 |
WO1996034888A1 (en) | 1996-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11504635A (ja) | コレステリルエステル転移タンパク質(cetp)活性の調節 | |
JP3825041B2 (ja) | 外来t−細胞エピトープを補助として用いた、自己タンパク質に対する抗体応答の誘発 | |
JP2633881B2 (ja) | 免疫調節組成物及びそれらの使用 | |
KR20050118669A (ko) | 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화 | |
US20040052809A1 (en) | Vaccine | |
US20140179900A1 (en) | Treatment of atherosclerosis with cholesterol ester transport protein mimotopes | |
JP2005508900A6 (ja) | ワクチン | |
JP2001508760A (ja) | アテローム性動脈硬化症治療用のプラスミド型ワクチン | |
JP2002523430A (ja) | 熱帯熱マラリア原虫に対する組換え多価マラリアワクチン | |
JP3910635B2 (ja) | Hdlコレステロールレベルを増大する方法 | |
US20030211997A1 (en) | Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same | |
WO2004080375A2 (en) | Vaccine therapy of atherosclerosis | |
AU747709B2 (en) | Xenogeneic cholesteryl ester transfer protein (CETP) for modulation of CETP activity | |
AU707752C (en) | Modulation of cholesteryl ester transfer protein (CETP) activity | |
WO2004081045A2 (en) | Vaccine related to modified apolipoprotein c-iii | |
HUE025186T2 (en) | Methods and methods using supramolecular constructs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050719 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051014 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060803 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090811 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090811 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090811 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100811 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |